Researchers from Shaanxi Panlong Pharmaceutical Group Co. Ltd., Shaanxi Pioneer Biotech Co. Ltd. and affiliated organizations presented the discovery and preclinical characterization of novel ...

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and ...

Carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa are a global threat to antimicrobial resistance and may be causative pathogens in cUTI. Cefepime-taniborbactam ...

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation ...

"The five factors with the highest odds of developing APN included obstructive and reflux uropathy, presentation to an acute care facility, urinary retention, history of UTI, and renal comorbidities.

Compared with meropenem, cefepime-taniborbactam is superior for microbiologic and clinical cure of complicated urinary tract infection, including acute pyelonephritis. Cefepime-taniborbactam is more ...

intravenous antibiotics Cefepime-enmetazobactam may be more effective than piperacillin-tazobactam in treating complicated UTI and acute pyelonephritis caused by organisms that produce ...

Exblifep is a combination product that consists of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. The Food and Drug Administration (FDA) has approved Exblifep ...

A young male cadaveric kidney transplant developed delayed graft function. In addition to fever, serial allograft biopsies revealed progressive infiltration of polymorphonuclear leukocytes. After ...

March is National Kidney Month, a time to raise awareness about your kidney health and generate support for those affected by conditions, including kidney stones, kidney infections and kidney disease.